Papillorenal syndrome medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 7: Line 7:




==Medical Management==
''
Evaluations Following Initial Diagnosis
To establish the extent of disease and needs in an individual diagnosed with PAX2-related disorder, the following are recommended if they have not already been completed:


Evaluation of renal structure by renal ultrasound examination
Measurement of renal function by serum electrolyte concentrations, BUN, and creatinine
Urinalysis to evaluate for the presence of blood and protein
Evaluation for vesicoureteral reflux, by voiding cystourethrogram (VCUG)
Dilated eye examination
Audiologic assessment (See Deafness and Hereditary Hearing Loss Overview for details of audiological assessment.)
Consultation with a clinical geneticist and/or genetic counselor
Treatment of Manifestations
A team approach that includes specialists in ophthalmology, nephrology, audiology, and clinical genetics is recommended.


Management is focused on preventing complications of end-stage renal disease (ESRD) and/or vision loss resulting from retinal detachment.


Ongoing treatment of hypertension and/or vesicoureteral reflux (if present) may preserve renal function.
ESRD is treated with renal replacement therapy (i.e., dialysis and/or renal transplantation).
Low vision experts can assist with the adaptive functioning of those with significant vision loss.
Prevention of Secondary Complications
Prevention of retinal detachment in those with congenital optic nerve abnormalities includes close follow up with an ophthalmologist and use of protective eyewear.


Surveillance
No disease-specific guidelines have been developed. The following ongoing evaluations are recommended in all individuals with PAX2-related disorder.


Follow up by a nephrologist to monitor renal function and blood pressure
Follow up by an ophthalmologist to monitor vision. Any change in vision could indicate a retinal detachment and should be treated as a medical emergency.
Audiometric evaluation with periodic follow-up
Agents/Circumstances to Avoid
Avoid the following:
Use of medications known to affect renal function (requires consultation with a specialist in nephrology)
Contact sports
Evaluation of Relatives at Risk
It is appropriate to clarify the genetic status of apparently asymptomatic at-risk relatives of an affected individual by molecular genetic testing of the PAX2 pathogenic variant in the family in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures.
See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.
Pregnancy Management
It is important that a female with PAX2-related disorder have a thorough renal evaluation prior to becoming pregnant. Individuals with clinical renal disease should consult with appropriate professionals including nephrologists and maternal-fetal medicine specialists to establish a plan for medical management during pregnancy.
Therapies Under Investigation
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.''


==References==
==References==

Revision as of 22:48, 28 September 2020

Papillorenal syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Differentiating Papillorenal syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Papillorenal syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Papillorenal syndrome medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Papillorenal syndrome medical therapy

CDC on Papillorenal syndrome medical therapy

Papillorenal syndrome medical therapy in the news

Blogs on Papillorenal syndrome medical therapy

Directions to Hospitals Treating Papillorenal syndrome

Risk calculators and risk factors for Papillorenal syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shivam Singla, M.D.[2]

Overview

Medical Management

Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with PAX2-related disorder, the following are recommended if they have not already been completed:

Evaluation of renal structure by renal ultrasound examination Measurement of renal function by serum electrolyte concentrations, BUN, and creatinine Urinalysis to evaluate for the presence of blood and protein Evaluation for vesicoureteral reflux, by voiding cystourethrogram (VCUG) Dilated eye examination Audiologic assessment (See Deafness and Hereditary Hearing Loss Overview for details of audiological assessment.) Consultation with a clinical geneticist and/or genetic counselor Treatment of Manifestations A team approach that includes specialists in ophthalmology, nephrology, audiology, and clinical genetics is recommended.

Management is focused on preventing complications of end-stage renal disease (ESRD) and/or vision loss resulting from retinal detachment.

Ongoing treatment of hypertension and/or vesicoureteral reflux (if present) may preserve renal function. ESRD is treated with renal replacement therapy (i.e., dialysis and/or renal transplantation). Low vision experts can assist with the adaptive functioning of those with significant vision loss. Prevention of Secondary Complications Prevention of retinal detachment in those with congenital optic nerve abnormalities includes close follow up with an ophthalmologist and use of protective eyewear.

Surveillance No disease-specific guidelines have been developed. The following ongoing evaluations are recommended in all individuals with PAX2-related disorder.

Follow up by a nephrologist to monitor renal function and blood pressure Follow up by an ophthalmologist to monitor vision. Any change in vision could indicate a retinal detachment and should be treated as a medical emergency. Audiometric evaluation with periodic follow-up Agents/Circumstances to Avoid Avoid the following:

Use of medications known to affect renal function (requires consultation with a specialist in nephrology) Contact sports Evaluation of Relatives at Risk It is appropriate to clarify the genetic status of apparently asymptomatic at-risk relatives of an affected individual by molecular genetic testing of the PAX2 pathogenic variant in the family in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures.

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Pregnancy Management It is important that a female with PAX2-related disorder have a thorough renal evaluation prior to becoming pregnant. Individuals with clinical renal disease should consult with appropriate professionals including nephrologists and maternal-fetal medicine specialists to establish a plan for medical management during pregnancy.

Therapies Under Investigation Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.

References

Template:WH Template:WS